Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD.

Rane P, Shields J, Heffernan M, Guo Y, Akbarian S, King JA.

Neuropharmacology. 2012 Jun;62(7):2409-12. doi: 10.1016/j.neuropharm.2012.01.026. Epub 2012 Feb 13.

PMID:
22353286
2.

Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability.

Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV.

Brain. 1991 Oct;114 ( Pt 5):2095-122.

PMID:
1933236
3.

L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction.

Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM.

Psychopharmacology (Berl). 1992;107(2-3):394-404.

PMID:
1615139
4.

Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.

Lewis SJ, Slabosz A, Robbins TW, Barker RA, Owen AM.

Neuropsychologia. 2005;43(6):823-32. Epub 2004 Dec 21.

PMID:
15716155
5.

Fronto-striatal cognitive deficits at different stages of Parkinson's disease.

Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, Lange KW, Robbins TW.

Brain. 1992 Dec;115 ( Pt 6):1727-51.

PMID:
1486458
6.

Cognitive components of reaction time in Parkinson's disease.

Jordan N, Sagar HJ, Cooper JA.

J Neurol Neurosurg Psychiatry. 1992 Aug;55(8):658-64.

7.
8.

Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates.

Decamp E, Schneider JS.

Eur J Neurosci. 2004 Sep;20(5):1371-8.

PMID:
15341609
9.

Long-lasting cognitive deficit induced by stress is alleviated by acute administration of antidepressants.

Nikiforuk A, Popik P.

Psychoneuroendocrinology. 2011 Jan;36(1):28-39. doi: 10.1016/j.psyneuen.2010.06.001. Epub 2010 Jun 26.

PMID:
20580164
10.

Cognitive and memory deficits in untreated Parkinson's disease and amyotrophic lateral sclerosis patients: a comparative study.

Hartikainen P, Helkala EL, Soininen H, Riekkinen P Sr.

J Neural Transm Park Dis Dement Sect. 1993;6(2):127-37.

PMID:
8117409
11.

5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats.

Hatcher PD, Brown VJ, Tait DS, Bate S, Overend P, Hagan JJ, Jones DN.

Psychopharmacology (Berl). 2005 Sep;181(2):253-9. Epub 2005 Oct 14.

PMID:
15846482
12.

Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex.

Newman LA, Darling J, McGaughy J.

Psychopharmacology (Berl). 2008 Sep;200(1):39-50. doi: 10.1007/s00213-008-1097-8. Epub 2008 Jun 22.

PMID:
18568443
13.

Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease.

Owen AM, Roberts AC, Hodges JR, Summers BA, Polkey CE, Robbins TW.

Brain. 1993 Oct;116 ( Pt 5):1159-75.

PMID:
8221053
14.

Deep brain stimulation and cognitive functions in Parkinson's disease: A three-year controlled study.

Zangaglia R, Pacchetti C, Pasotti C, Mancini F, Servello D, Sinforiani E, Cristina S, Sassi M, Nappi G.

Mov Disord. 2009 Aug 15;24(11):1621-8. doi: 10.1002/mds.22603.

PMID:
19514093
15.

Deficits of working memory during mental calculation in patients with Parkinson's disease.

Tamura I, Kikuchi S, Otsuki M, Kitagawa M, Tashiro K.

J Neurol Sci. 2003 May 15;209(1-2):19-23.

PMID:
12686397
16.
17.

Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance.

Pedersen CS, Goetghebeur P, Dias R.

J Neurosci Methods. 2009 Dec 15;185(1):66-9. doi: 10.1016/j.jneumeth.2009.09.014. Epub 2009 Sep 15.

PMID:
19761795
18.

Attentional set-shifting in Parkinson's disease patients with freezing of gait-acquisition and discrimination set learning deficits at the background?

Stefanova E, Ječmenica Lukić M, Ziropadja L, Marković V, Stojković T, Tomić A, Dragašević Mišković N, Kostić V.

J Int Neuropsychol Soc. 2014 Oct;20(9):929-36. doi: 10.1017/S1355617714000769. Epub 2014 Oct 13.

PMID:
25307410
19.

Liposomal-formulated curcumin [Lipocurc™] targeting HDAC (histone deacetylase) prevents apoptosis and improves motor deficits in Park 7 (DJ-1)-knockout rat model of Parkinson's disease: implications for epigenetics-based nanotechnology-driven drug platform.

Chiu S, Terpstra KJ, Bureau Y, Hou J, Raheb H, Cernvosky Z, Badmeav V, Copen J, Husni M, Woodbury-Farina M.

J Complement Integr Med. 2013 Nov 7;10. pii: /j/jcim.2013.10.issue-1/jcim-2013-0020/jcim-2013-0020.xml. doi: 10.1515/jcim-2013-0020.

PMID:
24200537
20.

PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats.

Rodefer JS, Murphy ER, Baxter MG.

Eur J Neurosci. 2005 Feb;21(4):1070-6.

PMID:
15787711
Items per page

Supplemental Content

Write to the Help Desk